                         SEQUENCE LISTING

<110>  Alkermes Pharma Ireland Limited
       LOSEY, Heather C.
       LOPES, Jared
       SUN, Lei
       WINQUIST, Raymond J.
 
<120>  Compositions and Methods for Subcutaneous Administration of Cancer Immunotherapy

<130>  P136792WO (4165.3081 WO)

<140>  PCT/EP2020/066234
<141>  2020-06-11

<150>  62/860,182
<151>  2019-06-11

<150>  62/924,356
<151>  2019-10-22

<150>  62/932,160
<151>  2019-11-07

<160>  3     

<170>  PatentIn version 3.5

<210>  1
<211>  303
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  1

Ser Lys Asn Phe His Leu Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn 
1               5                   10                  15      


Val Ile Val Leu Glu Leu Lys Gly Ser Glu Thr Thr Phe Met Cys Glu 
            20                  25                  30          


Tyr Ala Asp Glu Thr Ala Thr Ile Val Glu Phe Leu Asn Arg Trp Ile 
        35                  40                  45              


Thr Phe Ser Gln Ser Ile Ile Ser Thr Leu Thr Gly Gly Ser Ser Ser 
    50                  55                  60                  


Thr Lys Lys Thr Gln Leu Gln Leu Glu His Leu Leu Leu Asp Leu Gln 
65                  70                  75                  80  


Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys Asn Pro Lys Leu Thr Arg 
                85                  90                  95      


Met Leu Thr Phe Lys Phe Tyr Met Pro Lys Lys Ala Thr Glu Leu Lys 
            100                 105                 110         


His Leu Gln Cys Leu Glu Glu Glu Leu Lys Pro Leu Glu Glu Val Leu 
        115                 120                 125             


Asn Leu Ala Gln Gly Ser Gly Gly Gly Ser Glu Leu Cys Asp Asp Asp 
    130                 135                 140                 


Pro Pro Glu Ile Pro His Ala Thr Phe Lys Ala Met Ala Tyr Lys Glu 
145                 150                 155                 160 


Gly Thr Met Leu Asn Cys Glu Cys Lys Arg Gly Phe Arg Arg Ile Lys 
                165                 170                 175     


Ser Gly Ser Leu Tyr Met Leu Cys Thr Gly Asn Ser Ser His Ser Ser 
            180                 185                 190         


Trp Asp Asn Gln Cys Gln Cys Thr Ser Ser Ala Thr Arg Asn Thr Thr 
        195                 200                 205             


Lys Gln Val Thr Pro Gln Pro Glu Glu Gln Lys Glu Arg Lys Thr Thr 
    210                 215                 220                 


Glu Met Gln Ser Pro Met Gln Pro Val Asp Gln Ala Ser Leu Pro Gly 
225                 230                 235                 240 


His Cys Arg Glu Pro Pro Pro Trp Glu Asn Glu Ala Thr Glu Arg Ile 
                245                 250                 255     


Tyr His Phe Val Val Gly Gln Met Val Tyr Tyr Gln Cys Val Gln Gly 
            260                 265                 270         


Tyr Arg Ala Leu His Arg Gly Pro Ala Glu Ser Val Cys Lys Met Thr 
        275                 280                 285             


His Gly Lys Thr Arg Trp Thr Gln Pro Gln Leu Ile Cys Thr Gly 
    290                 295                 300             


<210>  2
<211>  309
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  2

Ser Lys Ser Phe Gln Leu Glu Asp Ala Glu Asn Phe Ile Ser Asn Ile 
1               5                   10                  15      


Arg Val Thr Val Val Lys Leu Lys Gly Ser Asp Asn Thr Phe Glu Cys 
            20                  25                  30          


Gln Phe Asp Asp Glu Ser Ala Thr Val Val Asp Phe Leu Arg Arg Trp 
        35                  40                  45              


Ile Ala Phe Cys Gln Ser Ile Ile Ser Thr Ser Pro Gln Gly Gly Ser 
    50                  55                  60                  


Ser Ser Thr Gln Gln Gln Gln Gln His Leu Glu Gln Leu Leu Met Asp 
65                  70                  75                  80  


Leu Gln Glu Leu Leu Ser Arg Met Glu Asn Tyr Arg Asn Leu Lys Leu 
                85                  90                  95      


Pro Arg Met Leu Thr Phe Lys Phe Tyr Leu Pro Lys Gln Ala Thr Glu 
            100                 105                 110         


Leu Lys Asp Leu Gln Cys Leu Glu Asp Glu Leu Gly Pro Leu Arg His 
        115                 120                 125             


Val Leu Asp Leu Thr Gln Gly Ser Gly Gly Gly Ser Glu Leu Cys Leu 
    130                 135                 140                 


Tyr Asp Pro Pro Glu Val Pro Asn Ala Thr Phe Lys Ala Leu Ser Tyr 
145                 150                 155                 160 


Lys Asn Gly Thr Ile Leu Asn Cys Glu Cys Lys Arg Gly Phe Arg Arg 
                165                 170                 175     


Leu Lys Glu Leu Val Tyr Met Arg Cys Leu Gly Asn Ser Trp Ser Ser 
            180                 185                 190         


Asn Cys Gln Cys Thr Ser Asn Ser His Asp Lys Ser Arg Lys Gln Val 
        195                 200                 205             


Thr Ala Gln Leu Glu His Gln Lys Glu Gln Gln Thr Thr Thr Asp Met 
    210                 215                 220                 


Gln Lys Pro Thr Gln Ser Met His Gln Glu Asn Leu Thr Gly His Cys 
225                 230                 235                 240 


Arg Glu Pro Pro Pro Trp Lys His Glu Asp Ser Lys Arg Ile Tyr His 
                245                 250                 255     


Phe Val Glu Gly Gln Ser Val His Tyr Glu Cys Ile Pro Gly Tyr Lys 
            260                 265                 270         


Ala Leu Gln Arg Gly Pro Ala Ile Ser Ile Cys Lys Met Lys Cys Gly 
        275                 280                 285             


Lys Thr Gly Trp Thr Gln Pro Gln Leu Thr Cys Val Asp Gly Ser His 
    290                 295                 300                 


His His His His His 
305                 


<210>  3
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  3

Met Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu 
1               5                   10                  15      


Val Thr Asn Ser 
            20  


